AstraZeneca China establishes a rare disease business unit, which may also undertake digestion and respiratory product lines in the future

Recently, AstraZeneca China established a new company named "Wuxi Ji Mo Pharmaceutical Co.

Overweight rare disease field layout

It is reported that AstraZeneca China announced to its employees that AstraZeneca China Rare Diseases Business Unit was formally established, and Wu Yun , the former head of the Strategic Project Management Office of AstraZeneca China Oncology Business Unit and the Executive Director of Marketing and Sales of Smetinib, was appointed as The head of the rare disease business department reports directly to AstraZeneca's global executive vice president, international business and China president Wang Lei

In December 2020, AstraZeneca announced the acquisition of Alexion in the form of US$39 billion in cash and stock.

Recently, AstraZeneca's long-acting C5 inhibitor Ultomiris was approved by the European Union for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in children & adolescents, and Ultomiris was obtained by the previous acquisition of Alexion

It is also worth mentioning that earlier this month, private equity giant Advent International and Singapore Government Investment Corporation (GIC) acquired Swedish rare disease company Orphan Biovitrum AB for 69 billion kronor ($8 billion), which happened to be through the acquisition of Alexion.

The new company may pave the way for the split digestion and breathing line

Jimo Pharmaceutical was registered in July 2021 with a registered capital of US$1 million.

In fact, since the first half of this year, AstraZeneca frequently reported that it would split its digestion and respiratory products business

In June, AstraZeneca China announced the adjustment of its organizational structure.

In fact, for a long time, the digestion and respiratory business have been AstraZeneca's important pillar pipelines